These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 18587251

  • 1. Comparative promoter methylation analysis of p53 target genes in urogenital cancers.
    Christoph F, Hinz S, Weikert S, Kempkensteffen C, Schostak M, Miller K, Schrader M.
    Urol Int; 2008; 80(4):398-404. PubMed ID: 18587251
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Frequent epigenetic inactivation of p53 target genes in seminomatous and nonseminomatous germ cell tumors.
    Christoph F, Kempkensteffen C, Weikert S, Krause H, Schostak M, Miller K, Schrader M.
    Cancer Lett; 2007 Mar 08; 247(1):137-42. PubMed ID: 16697107
    [Abstract] [Full Text] [Related]

  • 4. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
    Malekzadeh K, Sobti RC, Nikbakht M, Shekari M, Hosseini SA, Tamandani DK, Singh SK.
    Cancer Invest; 2009 Jan 08; 27(1):70-80. PubMed ID: 19160091
    [Abstract] [Full Text] [Related]

  • 5. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
    Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, Schrader M.
    Int J Cancer; 2006 Sep 15; 119(6):1396-402. PubMed ID: 16642478
    [Abstract] [Full Text] [Related]

  • 6. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
    Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K.
    Oncology; 2008 Sep 15; 75(3-4):145-51. PubMed ID: 18824877
    [Abstract] [Full Text] [Related]

  • 7. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
    Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ.
    J Urol; 2008 Sep 15; 180(3):1141-5. PubMed ID: 18639281
    [Abstract] [Full Text] [Related]

  • 8. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C, Kim YW, Ha YS, Kim IY, Kim YJ, Yun SJ, Moon SK, Bae SC, Kim WJ.
    J Surg Oncol; 2012 Mar 15; 105(4):425-30. PubMed ID: 22311819
    [Abstract] [Full Text] [Related]

  • 9. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
    Kawamoto K, Enokida H, Gotanda T, Kubo H, Nishiyama K, Kawahara M, Nakagawa M.
    Biochem Biophys Res Commun; 2006 Jan 20; 339(3):790-6. PubMed ID: 16316628
    [Abstract] [Full Text] [Related]

  • 10. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
    Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, Westra WH, Schoenberg M, Zahurak M, Goodman SN, Sidransky D.
    J Natl Cancer Inst; 2006 Jul 19; 98(14):996-1004. PubMed ID: 16849682
    [Abstract] [Full Text] [Related]

  • 11. Promoter hypermethylation identifies progression risk in bladder cancer.
    Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, Hamdy FC, Catto JW.
    Clin Cancer Res; 2007 Apr 01; 13(7):2046-53. PubMed ID: 17404085
    [Abstract] [Full Text] [Related]

  • 12. Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses.
    Lee MG, Huh JS, Chung SK, Lee JH, Byun DS, Ryu BK, Kang MJ, Chae KS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG.
    Oncogene; 2006 Sep 21; 25(42):5807-22. PubMed ID: 16909101
    [Abstract] [Full Text] [Related]

  • 13. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.
    Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI, Huland H, Jones PA, Liang G.
    Eur J Cancer; 2005 Nov 21; 41(17):2769-78. PubMed ID: 16242928
    [Abstract] [Full Text] [Related]

  • 14. EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder.
    Hinz S, Kempkensteffen C, Weikert S, Schostak M, Schrader M, Miller K, Christoph F.
    Tumour Biol; 2007 Nov 21; 28(3):151-7. PubMed ID: 17541304
    [Abstract] [Full Text] [Related]

  • 15. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
    Dhawan D, Hamdy FC, Rehman I, Patterson J, Cross SS, Feeley KM, Stephenson Y, Meuth M, Catto JW.
    J Pathol; 2006 Jul 21; 209(3):336-43. PubMed ID: 16639696
    [Abstract] [Full Text] [Related]

  • 16. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications.
    Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Köllermann J, Miller K, Schrader M.
    Clin Cancer Res; 2006 Sep 01; 12(17):5040-6. PubMed ID: 16951219
    [Abstract] [Full Text] [Related]

  • 17. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
    Kunze E, Von Bonin F, Werner C, Wendt M, Schlott T.
    Int J Mol Med; 2006 Jan 01; 17(1):3-13. PubMed ID: 16328005
    [Abstract] [Full Text] [Related]

  • 18. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
    Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M, Hamdy FC.
    J Clin Oncol; 2005 May 01; 23(13):2903-10. PubMed ID: 15753461
    [Abstract] [Full Text] [Related]

  • 19. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
    Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalgo ML, Toma MI, Huland H, Yoo C, Tsai YC, Nichols PW, Bochner BH, Jones PA, Liang G.
    Clin Cancer Res; 2004 Nov 15; 10(22):7457-65. PubMed ID: 15569975
    [Abstract] [Full Text] [Related]

  • 20. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
    Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, Daenen KL, Partouns-Hendriks IE, Stessels F, Louwagie J, Smits KM, Weijenberg MP, Sanduleanu S, Khalid-de Bakker CA, Oort FA, Meijer GA, Jonkers DM, Herman JG, de Bruïne AP, van Engeland M.
    J Natl Cancer Inst; 2009 Jul 01; 101(13):916-27. PubMed ID: 19535783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.